Fig. 7
From: STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway
The clinical significance of MUC1 and STON2 expression in ovarian cancer patients. a, b Cumulative survival probabilities (a, PFS and b, OS) were calculated using the Kaplan–Meier method (n = 145) based on STON2 and MUC1 expression. Survival rates were compared using log-rank test. Patients expressing low or high levels of MUC1 (a). Patients expressing high levels of STON2 combined with low MUC1 expression or high MUC1 expression (b). c A schematic model of the role of STON2 in regulating CSCs traits